Article
Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial.
The Lancet. Infectious diseases - 1 Sept 2024
Juraska Michal, Early Angela M, Li Li, Schaffner Stephen F, Lievens Marc, Khorgade Akanksha, Simpkins Brian, Hejazi Nima S, Benkeser David, Wang Qi, Mercer Laina D, Adjei Samuel, Agbenyega Tsiri, Anderson Scott, Ansong Daniel, Bii Dennis K, Buabeng Patrick B Y, English Sean, Fitzgerald Nicholas, Grimsby Jonna, Kariuki Simon K, Otieno Kephas, Roman François, Samuels Aaron M, Westercamp Nelli, Ockenhouse Christian F, Ofori-Anyinam Opokua, Lee Cynthia K, MacInnis Bronwyn L, Wirth Dyann F, Gilbert Peter B, Neafsey Daniel E
Abstract excerpt
BACKGROUND: The first licensed malaria vaccine, RTS,S/AS01E, confers moderate protection against symptomatic disease. Because many malaria infections are asymptomatic, we conducted a large-scale longitudinal parasite genotyping study of samples from a clinical trial exploring how vaccine dosing regimen affects vaccine efficacy. METHODS: Between Sept 28, 2017, and Sept 25, 2018, 1500 children aged 5-17 months were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.